Estrogen plus progestin did not reduce the risk for coronary heart disease in postmenopausal women

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p46
Academic Journal
The article focuses on the effectiveness of estrogen plus progestin in decreasing or increasing the risk for coronary heart disease in postmenopausal women. 16608 postmenopausal women who were 50 to 79 years of age had an intact uterus, and had resided in the same geographic area for about 3 years were examined. Patients were allocated to 1 daily tablet of oral conjugated equine estrogen, plus medroxyprogesterone acetate, or placebo. It was found that postmenopausal women were at increased risk for coronary heart disease (CHD) during the first year of estrogen plus progestin hormone therapy.


Related Articles

  • Estrogen plus progestin did not reduce the risk for coronary heart disease in postmenopausal women: COMMENTARY. Crandall, Carolyn // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p46 

    The article comments on a study conducted to examine the role of estrogen plus progestin in increasing or decreasing the risk of coronary heart disease (CHD) in postmenopausal women. The study provides information on additional clinical endpoints on women health. Menopausal women who choose to...

  • WHERE DO WE CURRENTLY STAND WITH ADVICE ON HORMONE REPLACEMENT THERAPY FOR WOMEN? Bozkurt, Biykem // Methodist DeBakey Cardiovascular Journal;Dec2010, Vol. 6 Issue 4, p21 

    The article reports on the risk factors for coronary artery disease (CAD) in women, and explores the relationship between CAD and hormone replacement therapy in postmenopausal women. As reported, certain risk factors for CAD that are unique to women include postmenopausal state, hormone...

  • Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear? Sengwee Toh; Hernández-Díaz, Sonia; Logan, Roger; Rossouw, Jacques E.; Hernán, Miguel A. // Annals of Internal Medicine;2/16/2010, Vol. 152 Issue 4, following p211 

    Background: Estrogen plus progestin therapy increases the risk for coronary heart disease (CHD) in postmenopausal women. However, this increased risk might be limited to the first years of use and to women who start therapy late in menopause. Objective: To estimate the effect of continuous...

  • Hormone use and cardiovascular impact--age matters.  // Patient Care;Mar2006, Vol. 40 Issue 3, p9 

    Presents the results of studies on the link of postmenopausal hormone therapy (HT) to coronary heart disease. Benefits of early start of HT therapy on women who are near their menopausal period; Outcome of a Women's Health Initiative Study of combined estrogen and progestin therapy among...

  • Hormone Replacement Therapy in Healthy Women. Huffman, Grace Brooke // American Family Physician;12/1/2002, Vol. 66 Issue 11, p2150 

    Presents abstracts of studies on hormone replacement therapy, published on the July 17, 2002 issue of the 'Journal of the American Medical Association.' 'Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative...

  • Estrogen-Progestin Therapy Fails to Slow Atherosclerosis.  // Life Extension;Feb2004, Vol. 10 Issue 2, p29 

    Reports that estrogen-progestin therapy has failed to slow the progression of coronary-artery atherosclerosis in post-menopausal women in the U.S. Indication in the progression of atherosclerosis seen on cardiac angiograms; Importance in preventing coronary artery disease after menopause;...

  • Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Richard L. Tannen; Mark G. Weiner; Dawei Xie; Kurt Barnhart // Human Reproduction;Jun2007, Vol. 22 Issue 6, p1769 

    BACKGROUND In the Womens Health Initiative Randomized Controlled Trial (WHI RCT), estrogen-only treatment compared with combined estrogen–progestin treatment resulted in less coronary artery disease, no increase in breast cancer and no reduction in colorectal cancer. Since we...

  • What do we tell our patients now about HRT? Lockwood, Charles J. // Contemporary OB/GYN;Aug2002, Vol. 47 Issue 8, p8 

    Discusses the findings of several studies concerning the risks associated with hormone replacement therapy (HRT). Medical conditions associated with the use of estrogen and progestin therapy; Overview of studies contradicting the association between HRT and coronary heart disease; Notions about...

  • Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy. Hlatky, Mark A.; Boothroyd, Derek; Vittinghoff, Eric; Sharp, Penny; Whooley, Mary A. // JAMA: Journal of the American Medical Association;2/6/2002, Vol. 287 Issue 5, p591 

    Presents a study to determine the effect on quality of life of estrogen plus progestin therapy used as secondary prevention in women with coronary artery disease. Context; Objective; Design, setting, and participants; Intervention; Main outcome measures; Results; Conclusion that hormone therapy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics